KAW strongly criticized the Food and Drug Administration’s (FDA) recent decision to approve without limitation the use of enrofloxin, a fluoroquinolone drug used to treat foodborne and other serious human infections, in swine.

In a letter to the FDA Commissioner, Dr. Andrew von Eschenbach, the KAW coalition highlighted that such use of the drug could compromise its effectiveness in humans and is inconsistent with FDA guidelines and recent rulings. KAW also calls for a Veterinary Medicine Advisory Committee (VMAC) review to reassess the FDA’s approval of enroflaxin and ultimately, given the public health risks associated with its use in animal agriculture, reverse the decision.